Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B

Journal of Hepatology

Volumn 39, Issue 2, 2003, Pages 222-230

  Myers, Robert P ^a,b   Tainturier, Marie Hélène ^a   Ratziu, Vlad ^a   Piton, Annie ^a   Thibault, Vincent ^a   Imbert Bismut, Françoise ^a   Messous, Djamila ^a   Charlotte, Frederic ^a   Di Martino, Vincent ^a   Benhamou, Yves ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Apolipoprotein A1; Biopsy; Diagnosis; Fibrosis; Haptoglobins; Hepatitis B; Histology; Receiver operating characteristic curve; Transaminases; Macroglobulins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; AMINOTRANSFERASE; APOLIPOPROTEIN A1; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM;

EID: 10744221863     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00171-5     Document Type: Article

References (41)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
2. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, editor. Viral hepatitis. New York, NY: Marcel Dekker; 1997. p. 315-30.
3. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
4. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
5. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-47.
6. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984;101:613-6.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
8. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999;30:770-4.
9. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396-400.
10. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-5.
11. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
12. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000;32:1403-8.
13. ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet 1998;351:1914-8.
14. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B? Liver 1997;17:83-7.
15. Giustina G, Fattovich G, De Paoli M, Guido M, Favarato S, Rugge M, et al. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy. Int J Clin Lab Res 1996;26:33-6.
16. Pontinha N, Pessegueiro H, Barros H. Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B. Scand J Clin Lab Invest 1999;59:343-7.
17. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999;14:138-45.
18. Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1998;13:680-4.
19. Ding H, Chen Y, Feng X, Liu D, Wu A, Zhang L. Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2001;9:78-80.
20. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
21. Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003;17:721-5.
22. Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al. The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: prospective validation in 534 patients (abstract). Hepatology 2002;36:351A.
23. Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al. Life is possible without biopsy in patients with chronic hepatitis C: validation of biochemical markers of liver fibrosis and activity in 1570 patients and blood donors (abstract). Hepatology 2002;36:351A.
24. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated interferon alfa-2b and ribavirin combination (abstract). Hepatology 2002;36:351A.
25. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 2002;9:128-33.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
27. Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem 1986;24:481-95.
28. Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1). J Clin Chem Clin Biochem 1986;24:497-510.
29. Persijn JP, van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem 1976;14:421-7.
30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
31. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4.
32. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987;7:302-6.
33. Franck PF, Steen G, Lombarts AJ, Souverijn JH, van Wermeskerken RK. Multicenter harmonization of common enzyme results by fresh patient-pool sera. Clin Chem 1998;44:614-21.
34. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;2:3.
35. Arico S, Aragona M, Rizzetto M, Caredda F, Zanetti A, Marinucci G, et al. Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. Lancet 1985;2:356-8.
36. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994;39:2426-32.
37. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Colch) 1998;95:179-86.
38. Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991;100:1397-402.
39. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28:439-42.
40. Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 1996;23:1232-8.
41. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999;276:G1059-GF1068.